Health Canada approves Keytruda for adjuvant treatment of stage IIB or IIC melanoma following complete resection
Merck Inc. announced that Health Canada has granted approval for Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection
This approval is based on the results from the Phase III KEYNOTE-716 trial, which demonstrated a statistically significant improvement in recurrence-free survival (RFS).
In 2022, an estimated 9,000 Canadians will be diagnosed with melanoma, a form of cancer that takes place when melanocytes, the cells responsible for melanin production, start to grow uncontrollably and develop into a tumour. Although it is the least common of all skin cancers, melanoma is the most serious type and early diagnosis and treatment are critical.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins